Kymera Therapeutics Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
-12.1%projected annual EPS growth
Analyst Coverage
22analysts covering
FY Revenue (est.)
$106.2Mnext fiscal year
FY EPS (est.)
-$3.80next fiscal year
Monitoring Framework
Key Performance Indicators
Cash and Marketable Securities Balance Quarterly1.6BTarget: Maintain sufficient runway into 2029
KT-621 BROADEN2 Phase 2b Trial Enrollment Progress Annually
Collaboration Revenue Quarterly34.4MTarget: Maximize milestone achievements under Gilead and Sanofi partnerships
Watch Items
- KT-621 BROADEN2 Phase 2b Clinical Trial Data in Atopic DermatitisTrigger: Topline data release expected by mid-2027Action: Evaluate efficacy (EASI score improvements) and safety profile compared to biologics to confirm oral competitive advantage.
- KT-621 BREADTH Phase 2b Clinical Trial Data in AsthmaTrigger: Topline data release expected in late 2027Action: Assess percent change from baseline in pre-bronchodilator FEV1 to validate STAT6 degradation in pulmonary indications.
- KT-579 Phase 1 Healthy Volunteer Trial DataTrigger: Data readout expected in 2H26Action: Review safety, tolerability, and pharmacokinetics/pharmacodynamics of the oral IRF5 degrader.
- KT-485 Phase 1 Trial Initiation (Sanofi Collaboration)Trigger: First participant dosed in Q2 2026Action: Monitor clinical progression and milestone recognition under the Sanofi partnership.
Research as of 2 Sep 2026